April 29, 2020 / 6:17 AM / a month ago

AstraZeneca beats first-quarter profit estimates, retains 2020 forecast

April 29 (Reuters) - AstraZeneca on Wednesday beat analysts’ estimates for first-quarter profit and reiterated its outlook for 2020, as demand for the company’s newer medicines remained steady.

Product sales for the three months ended March 31 rose 17% to $6.31 billion, on a constant-currency basis, marking the seventh consecutive quarter of growth.

The company’s core earnings rose 21% to $1.05 per share, while total revenue, which also includes payments from tie-ups, rose 17% to $6.35 billion from year earlier.

Analysts on average had expected core earnings of 94 cents per share and product sales of $5.89 billion, according to a company provided consensus of 22 analysts.

AstraZeneca is testing two of its approved treatments as a therapy to help treat the disease caused by the novel coronavirus.

Reporting by Pushkala Aripaka, Ankur Banerjee in Bengaluru and Ludwig Burger in Frankfurt; Editing by Sriraj Kalluvila

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below